Habib J. Dable - Jun 2, 2025 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Director
Signature
/s/ Charles N. York II, as Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
Jun 2, 2025
Transactions value $
$0
Form type
4
Date filed
6/4/2025, 05:53 PM
Previous filing
Jun 21, 2024
Next filing
Jun 6, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dable Habib J Director 1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE /s/ Charles N. York II, as Attorney-in-Fact 2025-06-04 0001690773

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Stock Option (right to buy Common Stock) Award $0 +22.5K $0.00 22.5K Jun 2, 2025 Common Stock 22.5K $7.01 Direct F1
transaction DAWN Restricted Stock Unit (RSU) Award $0 +15K $0.00 15K Jun 2, 2025 Common Stock 15K $0.00 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/12th of the total grant on each monthly anniversary, beginning on July 2, 2025, subject to the Reporting Person's provision of service to the Issuer on each option vesting date.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F3 The RSUs will vest as to 100% of the award on the earlier of (i) June 2, 2026 and (ii) the date of the Issuer's 2026 annual meeting of stockholders (in each case, the "RSU Vesting Date"), subject to the Reporting Person's provision of services to the Issuer on each RSU Vesting Date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.
F4 RSUs do not expire; they either vest or are canceled prior to the RSU Vesting Date.